GEN Exclusives

More »

GEN News Highlights

More »
Dec 22, 2008

Forest Buys CNS Disease-Related Drug for $75M Upfront

  • Forest Laboratories is paying $75 million to Pierre Fabre Medicament for rights to develop and commercialize F2695 in the U.S. and Canada. F2695 is a selective norepinephrine and serotonin reuptake inhibitor being tested for the treatment of depression and other central nervous system disorders.

    Forest will also pay milestone fees and royalties. Forest will assume responsibility for the clinical development and commercialization of F2695, while Pierre Fabre will fund all preclinical development and drug substance manufacturing activities worldwide.

    “We are highly encouraged by the strong clinical antidepressant activity and good tolerability exhibited by F2695 in the recently completed placebo-controlled, double-blind Phase II study,” says Howard Solomon, chairman and CEO of Forest. “We look forward to initiating Phase III studies with F2695 next year.”

    In a recently completed European placebo-controlled, double-blind Phase II study of F2695 in over 550 patients with major depressive disorder, the compound demonstrated statistically significant improvement compared to placebo regarding change from baseline in total score on the Montgomery-Asberg Depression Rating Scale, according to the firms.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?